However, our results imply that the enhanced secretion of exosomes from cancer cells is likely driven by cancer-specific mechanisms, such as the Src–Alix interaction, and targeting this pathway may be an attractive therapeutic strategy that may serve to inhibit not only tumor progression but also cancer metastasis mediated by exosomes. Here, PDCD6IP is linked to neoplasm.